The obesity market size reached a value of USD 17.1 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 76.6 million by 2035, exhibiting a growth rate (CAGR) of 14.62% during 2025-2035.

By 2025, the fight against obesity has become much smarter and more connected, with new meds, app-driven tools, and better coverage all coming together. Once seen mainly as an everyday weight issue, obesity is now treated as a long-term disease that needs ongoing support, and the fresh mix of therapies and care models reflects that change. Drug developers are still at the front, pushing the biggest breakthroughs. Alongside familiar injectables, several easy-to-swallow pills are finishing late-stage tests and could soon land in bathrooms. These oral options promise the same effectiveness with far less hassle, hinting that simpler, user-friendly solutions are claiming center stage. On top of that, powerhouse companies are fine-tuning combo drugs that hit two or three body signals at once, aiming for quicker, stronger outcomes.

Tech is equally hard at work in the 2025 landscape. Smart phones, wrist bands, and online coaches now log meals, cheer on movement, and sync directly with doctors. These digital buddies dish out custom meal plans, show weight changes in real time, and keep motivation high-clearly vital for lasting habit shifts. Blending these apps with traditional clinic visits shows a bold new picture of how obesity care can and should feel. Another big trend today is that people everywhere are getting more access to weight-care options. North America still leads the market, but Asia-Pacific, Latin America, and parts of Africa are closing the gap thanks to clearer rules and better ways to pay for care. In fact, some countries are handing out obesity medicines right at neighborhood clinics and pharmacies, cutting down red tape and giving community teams a bigger role. Still, serious roadblocks are in the way. Premium prices for new drugs and mixed treatment packages show why plans that cover costs-in-full or at least lower the out-of-pocket hit are a must. On top of that, the old stigma still lingers, and keeping patients on track over months and years calls for ongoing care that joins medical, social, and public-education efforts.

Request to get a PDF Sample Report: https://www.imarcgroup.com/obesity-market/requestsample

The report also provides a detailed analysis of the current obesity marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Buy the full Obesity Market Epidemiology Report: https://www.imarcgroup.com/checkout?id=27912&method=809

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the obesity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the obesity market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape

The competitive landscape of the obesity market has been studied in the report with the detailed profiles of the key players operating in the market.

Roche
VIVUS
Currax Pharma
Novo Nordisk
Amgen
Eli Lilly and Company
Boehringer Ingelheim
Carmot Therapeutics

7 Major Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145